Aarti Drugs DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.83×	0.92×	0.79×	0.73×	0.74×
	0.87×	0.87×	0.92×	0.89×	0.88×
	9.8%	9.4%	9.7%	10.5%	9.4%
	0.95×	0.95×	0.95×	1.04×	1.22×
	1.82×	1.82×	1.88×	1.90×	2.03×
	12.3%	13.1%	12.6%	13.4%	15.2%
	13.4%	13.4%	12.7%	13.9%	15.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health

₹ CrorePeersALIVUS AARTIPHARM ADVENZYMES AGARWALEYE AKUMS APLLTD CORONA HCGMcap ₹4,098 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.73	0.79	0.92	0.83
Interest Burden (Pretax/EBIT) ×	0.88	0.89	0.92	0.87	0.87
EBIT Margin %	9.40	10.48	9.69	9.44	9.81
Asset Turnover ×	1.22	1.04	0.95	0.95	0.95
Financial Leverage (Assets/Equity) ×	2.03	1.90	1.88	1.82	1.82
ROE (5-step product, year-end total equity) %	15.17	13.39	12.58	13.12	12.32
ROE (owners' profit / average owners' equity) %	15.37	13.86	12.69	13.36	13.36

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.